Researchers identify source of nerve damage in multiple sclerosis
Researchers identify source of nerve damage in multiple sclerosis
Orange County Register Fri, 20 Oct 2006 6:46 PM PDT
The damage to nerve fibers that accompanies multiple sclerosis is caused, in part, by the body's own immune system.
Handling The Ups And Downs Of Multiple Sclerosis - Book That Deals Exclusively With The Emotional Impact Of Multiple
Medical News Today Fri, 20 Oct 2006 2:07 PM PDT
The emotional impacts of MS are serious and widespread. Over 50% of MS patients suffer from depression and up to 90% experience anxiety. Handling the ups and downs of MS can be both physically and emotionally challenging. In fact, many find the emotional impact of the disease more debilitating than the physical symptoms. Yet, to date, no book has focused solely on this important topic, until
Orange County Register Fri, 20 Oct 2006 6:46 PM PDT
The damage to nerve fibers that accompanies multiple sclerosis is caused, in part, by the body's own immune system.
AVONEX(R), The #1 Prescribed Multiple Sclerosis Therapy Worldwide, Improves Patient Convenience RedNova Fri, 20 Oct 2006 12:11 PM PDT AVONEX® (Interferon beta-1a), the most prescribed multiple sclerosis (MS) therapy worldwide, may now be stored at room temperature (up to 77°F or 25°C) in its prefilled formulation for a period up to 7 days. |
Handling The Ups And Downs Of Multiple Sclerosis - Book That Deals Exclusively With The Emotional Impact Of Multiple
Medical News Today Fri, 20 Oct 2006 2:07 PM PDT
The emotional impacts of MS are serious and widespread. Over 50% of MS patients suffer from depression and up to 90% experience anxiety. Handling the ups and downs of MS can be both physically and emotionally challenging. In fact, many find the emotional impact of the disease more debilitating than the physical symptoms. Yet, to date, no book has focused solely on this important topic, until
GW Pharma files Sativex in Canada for cancer pain PharmaBiz Fri, 20 Oct 2006 9:49 PM PDT GW Pharmaceuticals plc and Bayer HealthCare, Pharmaceuticals Division - Canada (Bayer) announce that GW has submitted a regulatory application in Canada for Sativex to seek approval for a new indication for the treatment of pain in patients with advanced cancer that has not been adequately relieved by opioid medications. |
0 Comments:
Post a Comment
<< Home